Candidate exhibits a novel mechanism of action and differs considerably from previously approved drugs
Open Orphan – a specialists in testing infectious and respiratory disease products using human challenge clinical trials – has announced that its subsidiary, hVIVO, has signed a £6.2m contract with a US-based biotechnology company to test its antiviral candidate.
‘The human challenge study’ is expected to commence in 2022 and will be conducted at hVIVO’s state-of-the-art facilities in London. The Company expects the revenue from the contract to be recognised across 2022 and 2023.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).